Investigation of the bioequivalence of two lansoprazole formulations in healthy Chinese volunteers after a single oral administration
Source abstract
Abstract
The objective of this study was to compare two lansoprazole products (the reference brand enteric-coated capsules and the test generic enteric-coated tablets), and the key pharmacokinetic (PK) parameters for both formulations and their metabolites were assessed. The study used an open-label, randomized two-period crossover design with an 8-day washout period between doses in 24 healthy subjects under fasting conditions. The concentration of lansoprazole and its two metabolites was determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. The in vitro release of lansoprazole from the test and reference formulations was within the acceptable limits. The relationship between concentration and peak area ratio was found to be linear within the range for lansoprazole and metabolites. The point estimates (ratios of geometric mean) of lansoprazole and two main metabolites were between 94.3% and 105.1% for AUC0-t, AUC0-∞, and Cmax. No statistically significant difference between the two formulations was found. The results of in vitro and in vivo suggested equivalent clinical efficacy of the two brands.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Helicobacter pylori-related gastroenterology studies · Microscopic Colitis · Gastroesophageal reflux and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
References (21)
Show source-provided references
1. Alai M · Int J Nanomedicine · 2015 · 10 · 4029
2. 10.1002/j.1552-4604.2000.tb05980.x10.1002/j.1552-4604.2000.tb05980.x ↗
3. 10.1208/s12248-013-9499-x10.1208/s12248-013-9499-x ↗
4. 10.1016/S0939-6411(00)00152-110.1016/S0939-6411(00)00152-1 ↗
5. 10.1046/j.1365-2036.2002.01138.x10.1046/j.1365-2036.2002.01138.x ↗
6. 10.1517/14656566.2.10.166310.1517/14656566.2.10.1663 ↗
7. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population, 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003066.pdf.
8. ICH. 1996. ICH harmonization tripartite guideline. Guidelines for good clinical practice. International Conference of Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human uses, Geneva, Switzerland.
9. 10.1254/fpj.131.14910.1254/fpj.131.149 ↗
10. 10.1111/j.1572-0241.2003.08783.x10.1111/j.1572-0241.2003.08783.x ↗
11. 10.1016/S1570-0232(02)00711-010.1016/S1570-0232(02)00711-0 ↗
12. 10.1208/s12248-014-9570-210.1208/s12248-014-9570-2 ↗
13. Schulz HU · Int J Clin Pharmacol Ther Toxicol · 1992 · 30 · S1
14. 10.1016/j.jchromb.2004.11.05210.1016/j.jchromb.2004.11.052 ↗
15. USP DI, 18th Edition, Lansoprazole, Vol. 1, United states Pharmacopoeial Convention Inc., Rockville, MD, 1998, pp. 1795–1797.
16. 10.1016/S1086-5802(16)31036-110.1016/S1086-5802(16)31036-1 ↗
17. World Medical Association · 2008
18. 10.1016/j.jpba.2008.09.04610.1016/j.jpba.2008.09.046 ↗
19. Zeng Y · Int J Physiol Pathophysiol Pharmacol · 2015 · 7 · 158
20. 10.1007/s13318-012-0115-810.1007/s13318-012-0115-8 ↗
21. 10.5414/CP20205910.5414/CP202059 ↗